A practical reference on Epithalamin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-29 and is reviewed periodically as new material appears.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
Storage and handling follow conventional peptide practice. Lyophilized epitalon is typically kept refrigerated or frozen, protected from moisture and light, and allowed to equilibrate to room temperature before opening to avoid condensation. Once dissolved, aqueous solutions are usually stored cold and used within a short period, since dilute peptide solutions can support microbial growth and may slowly degrade. The absence of cysteine and methionine reduces, but does not eliminate, oxidation concerns during long-term storage.
Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four amino acid residues |
| Residue sequence | Ala-Glu-Asp-Gly | Abbreviated AEDG |
| Approximate mass | 390.35 Da | Monoisotopic, free base form |
| Parent preparation | Epithalamin extract | Derived from pineal tissue |
| Common spelling variants | Epithalon, epithalone, AEDG | Affects literature retrieval |
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
Typical storage for the lyophilized powder is −20 °C or lower, in a sealed container protected from light and moisture. Hygroscopic material should be allowed to equilibrate to room temperature before the vial is opened, which limits condensation on the contents. Working solutions are commonly divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Dilute solutions are more prone to adsorption onto plastic surfaces and to loss during filtration, so procedures that minimize transfers and use low-binding labware are preferable.
Reversed-phase high-performance liquid chromatography is the standard approach for assessing purity, usually with ultraviolet detection near 214 nm, where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the molecular mass and helps reveal truncation or deletion byproducts. Amino acid analysis can verify composition, and counterion content is sometimes measured because peptides purified with trifluoroacetic acid retain variable amounts of that salt. Purity figures reported without a stated method and detection wavelength are difficult to interpret.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
=== San Antonio Nathan Shock Center === The San Antonio Nathan Shock Center (NSC) is one of only eight National Institute on Aging (NIA)-funded Nathan Shock Centers of Excellence in the Basic Biology of Aging in the United States. Since its establishment in 1995, the Center has served as an internationally recognized resource dedicated to advancing the fundamental biology of aging and accelerating the development of interventions that promote healthy aging and extend healthspan. The overarching mission of the Center is to identify the molecular, cellular, and physiological mechanisms that drive the aging process and translate these discoveries into strategies that delay or prevent age-associated diseases and functional decline. The San Antonio Nathan Shock Center provides investigators with an integrated, "one-stop-shop" research infrastructure that supports every stage of aging research—from experimental design and animal model development to functional phenotyping, pathology, metabolism, pharmacology, and data interpretation. This comprehensive approach enables investigators to conduct rigorous, multidisciplinary studies that examine lifespan, healthspan, and the biological mechanisms underlying aging. By integrating specialized expertise and state-of-the-art technologies within a single research environment, the Center accelerates scientific discovery while promoting collaboration among investigators locally, nationally, and internationally. The Center is organized around six highly integrated research cores that provide specialized services and scientific expertise.
=== Post-translational modifications === Most programs available for protein analysis are not written for proteins that have undergone post-translational modifications. Some programs will accept post-translational modifications to aid in protein identification but then ignore the modification during further protein analysis. It is important to account for these modifications since they can affect the protein's structure. In turn, computational analysis of post-translational modifications has gained the attention of the scientific community. The current post-translational modification programs are only predictive. Chemists, biologists and computer scientists are working together to create and introduce new pipelines that allow for analysis of post-translational modifications that have been experimentally identified for their effect on the protein's structure and function.
Originally, the term radiation protection referred only to ionizing radiation. Today, non-ionizing radiation is also included and is the responsibility of the Federal Office for Radiation Protection, the Radiation Protection Division of the Federal Office of Public Health and the Ministry of Climate Action and Energy (Austria). The project collected, evaluated and compared data on the legal situation in all European countries (47 countries plus Germany) and major non-European countries (China, India, Australia, Japan, Canada, New Zealand and the USA) regarding electric, magnetic and electromagnetic fields (EMF) and optical radiation (OS). The results were very different and in some cases deviated from the recommendations of the International Commission on Non-Ionizing Radiation Protection (ICNIRP).
=== Cushing's Disease === Corticotropic cells can have detrimental effects on the body if they express too much or too little ACTH. One such example is Cushing's disease, which can result from overproduction of ACTH in the corticotropes due to pituitary tumors known as corticotroph adenomas; this is the cause for roughly two-thirds of those diagnosed with Cushing's disease. It is also possible that this disease can result from production of ACTH in a non-pituitary tumor, known as ectopic production, or the adrenal glands can overproduce cortisol due to an adrenal tumor. This overproduction of ACTH causes an increase in cortisol levels due to increased glucocorticoid synthesis in the adrenal cortex resulting in several associated symptoms. Symptoms of Cushing's disease include:
Sources: en.wikipedia.org
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MDDMA's dose as greater than 150 mg orally and its duration as unknown. Findings on the effects of MDDMA are very mixed. In two reports, with 150 mg and 1,000 mg both orally, no effects whatsoever occurred. In another report, 550 mg orally resulted in very negative effects. Finally, two people who used 200 mg orally found that it produced very pleasant effects for 20 minutes, wore off, but then resurged to produce even stronger effects 4 hours later. The higher-dose reports were communicated to Shulgin anonymously and he was uncertain whether the actual substance employed was indeed MDDMA. More research seems necessary to characterize MDDMA, but Shulgin expected that a "pretty hefty dose" would be required for it to produce effects.
June 23 – COVID-19 pandemic – Washington reports their first case of the Lineage P.1 Gamma variant in an unvaccinated Clallam County resident who traveled out of the state. June 24 Surfside condominium building collapse – A 12-story condominium apartment building in Surfside, Florida partially collapses. At the official end of search on July 23, the death toll is 97, with one further person unaccounted for. A pedestrian bridge on Interstate 295 collapses in northeastern Washington, D.C., injuring five. Infrastructure policy of the Joe Biden administration: President Biden announces that he has reached a bipartisan infrastructure deal with Senators. Aftermath of the January 6 United States Capitol attack – Over 500 suspects have been arrested since the Capitol riot. U.S. Attorney General Merrick Garland announces that the first suspect is arrested for assaulting media during the events of January 6. The Appellate Division of the New York Supreme Court suspends former New York City Mayor Rudy Giuliani from practicing law over his false claims about the 2020 election. Microsoft unveils Windows 11, the latest generation of its computer operating system. The Federal Aviation Administration approves a request to rename McCarran International Airport in Las Vegas, currently the seventh-busiest airport by passenger traffic in the United States, to Harry Reid International Airport. June 25 Defending Stanley Cup champion Tampa Bay Lightning advance to the Stanley Cup Finals to face the Montreal Canadiens.
Robertson had been rejected as a candidate for the chair in physiology at Johns Hopkins University because his reputation had been "tarnished" not only by his decision to patent tethelin, but also by his association with its potential commercial exploitation. Robertson also learned that his long post-graduate association with American universities — rather than the (preferred at the time) post-graduate work in United Kingdom — had caused his application to join the newly founded Walter and Eliza Hall Institute of Research in Pathology and Medicine, as its first Director, to be rejected in favour of the successful candidate, Sydney W. Patterson M.B. B.S., M.D., D.Sc., who had studied in the UK at University College London, and had gained his Doctor of Science (D.Sc.) from the University of London. With a desire to return to Australia — and hoping to apply his acquired academic, administrative, and research skills, talents, and expertise to Australian circumstances — he accepted (in June 1919) the University of Adelaide's (April 1919) offer of a Chair, vacant since the (20 March 1919) death of Robertson's father-in-law, Sir Edward Stirling, who had been the university's Professor of Physiology; and, where, in the interim, Charles Kellaway, M.B. B.S., M.D., M.S. of Melbourne, had served as locum.
== Political positions == Kerry-Lynne Findlay has positioned herself as right-wing populist, socially conservative, and a Blue Tory. She has described herself as a “reliable Conservative,” and an outsider taking on “insiders” with a “hidden liberal agenda” and “mainstream media gatekeepers.” Findlay has emphasized “faith, family, and freedom” as guiding her leadership, and is politically compared to former British Columbia premier Bill Vander Zalm.
=== Animal studies === Multiple animal studies have investigated the biological activity of D-ribose-L-cysteine in models of oxidative stress and metabolic injury. These studies have reported that D-ribose-L-cysteine supplementation increases intracellular and tissue glutathione levels, improves antioxidant enzyme activity, and reduces markers of oxidative damage in rodents. In several experimental models, D-ribose-L-cysteine demonstrated equal or greater glutathione-enhancing effects compared with N-acetylcysteine, though these findings are limited to preclinical settings.
Sources: en.wikipedia.org
It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.
No. Epithalamin is a heterogeneous extract containing many peptides, while epitalon is a single synthesised tetrapeptide. Publications sometimes treat findings from the two as equivalent, which is a common source of confusion. Their compositions differ and they are not interchangeable in analytical terms.
Most published work uses cell cultures or rodents because those models are faster and less costly to run. The few human trials that have been reported are small, and several lack control groups or blinding. This restricts what can reasonably be concluded about effects in people.
Identity is normally confirmed by mass spectrometry, which checks the measured mass against the expected value near 390 daltons. Reverse-phase high-performance liquid chromatography is used alongside it to assess purity. Amino acid analysis can provide additional composition data.